US · biotechnology · cell therapy
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · May 2026 · $122M
ARCH Venture Partners lead, Hatteras Venture Partners lead, Newpath Partners lead, Alexandria Venture Investments
Reported by TechStartups
Missing a round, or an investor who was in one? Tell us.